Institute of Pharmacology and Toxicology Academy of Military Medical Sciences Pla China

Academy of Military Medical Sciences

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.l.a.

Institute of Pharmacology and Toxicology Academy of Military Medical Science P.l.a. China

Institute of Pharmacology

Toxicology Academy of Military Medical Sciences P.l.a., China

Institute of Pharmacology and Toxicology Academy of Military Science P.l.a. China

Rifang Yang

Liuhong Yun

Rusheng Zhao

Jin Li

Ning Wu

Hui Zhu

Cheng Zhang

Nan Zhao

Yunfeng Li

Rui Song

Youzhi Zhang

Ruibin Su

Yongzhen Li

Juanjuan Qin

Wei Liu

Hai Feng Wang

Peng Li

Lin Wang

Gang Hu

Juan Wang

Lijun Liu

Rui Xue

Yuan Yan

Hongxia Chen

Zhenzhen Wang

Fulin Li

Jianquan Zheng

Li Yuan

Shuzhuo Zhang

Xiaodan Xu

Xiaomei Zhuang

Jiazhi Yao

Chong Pang

Huasong Feng

Xingchun Tang

Huamei He

Wenyu Cui

Qixiu Gao

Chaoliang Long

Xinqiang Lu

Haoshan Wang

Zhongyao Feng

Guoxing Dong

Zengliang Jin

Hai Wang

Zengling Jin

The invention belongs to the field of medicine and chemical industry and relates to a 4,4-diphenylpiperidine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and uses thereof. In particular, the invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof. In the present invention, the compound or pharmaceutically acceptable salt thereof and the pharmaceutical composition have significant activity in blocking an N-type calcium channel, and have good pharmacokinetic properties, can effectively relieve pain, and have a potential as a new medicament for prevention or treatment of pain, stroke, cerebral ischemia, alcohol addiction, alcoholism, kidney disease, addictive disorder caused by analgesic or tolerance disorder caused by analgesic. 

4,4-diphenylpiperidine compounds or pharmaceutically acceptable salts thereof, pharmaceutical compositions and uses thereof

The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction. 

Dopamine D3 receptor ligands and preparation and medical uses of the same

Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R, R, Rand Rare defined as in the specification. Preparation methods of said compounds and use of said compounds in treating and/or preventing central nervous system disease associated with TSPO functional disorder 

2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof

Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof.  The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.

1-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives, preparation methods and uses thereof

The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.

The present invention provides amine derivatives represented by formula I, its isomers, racemes or optical isomers, pharmaceutical salts thereof, its amides or esters, pharmaceutical compositions containing said compounds and the preparation methods thereof. The invention also relates to the use of the above mentioned compounds in the preparation of drugs for the prophylaxis or treatment of cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasm as well as ischemic and anoxic nerve injury. The above compounds can be used to treat hypertension, angina diaphragmatic, myocardial infarction, congestive heart failure, arrhythmia, diabetes, spasmodic bronchial diseases, spasmodic bladder or ureter diseases, and depression. 

Amine derivative with potassium channel regulatory function, its preparation and use

Growing community of inventors

Beijing, China

Rifang Yang